TScan Therapeutics to Participate in Upcoming Investor Conferences

TScan Therapeutics to Participate in Upcoming Investor Conferences

By

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

By

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

By

TScan Therapeutics Announces Transition of Chief Financial Officer

By

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

By

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting

By

TScan Therapeutics Announces Closing of Public Offering

By

TScan Therapeutics to Participate in the Jefferies Healthcare Conference

By

TScan Therapeutics Announces Pricing of $140 Million Public Offering

By

TScan Therapeutics Announces Launch of Proposed Public Offering

By